Skip to main content

Table 4 Association between FGF-23 and cardiovascular disease

From: Soluble Klotho is not independently associated with cardiovascular disease in a population of dialysis patients

AACscore Beta CI p-value
Model 1. Crude association 0.72 -0.13-1.57 0.10
Model 2. (+ Confounders)* 0.49 -0.35-1.34 0.25
CACscore Beta CI p-value
Model 1. Crude association 0.25 -0.13-0.63 0.20
Model 2. (+Confounders)* 0.001 -0.40-0.40 1.00
LVMI Beta CI p-value
Model 1. Crude association 0.48 -5.79-6.75 0.88
Model 2. (+Confounders)* -0.70 -7.40-6.00 0.84
LV-dysfunction (LVEF < 45%) OR CI p-value
Model 1. Crude association 0.68 0.40-1.16 0.16
Model 2. (+Confounders)* 0.51 0.26-1.01 0.053
CAD (any vessel occluded) OR CI p-value
Model 1. Crude association 0.94 0.66-0.63 0.20
Model 2. (+Confounders)* 0.65 0.41-1.04 0.08
  1. Beta’s represent changes in LnFGF-23.
  2. AACscore; Abdominal aorta calcification score, CACscore; Coronary artery calcification score, LVMI; Left ventricular mass index, LV-dysfunction; Left ventricular dysfunction. CAD; Coronary artery disease.
  3. Model 1; sKlotho. *Model 2; + age, gender, (ln)dialysis vintage, dialysis type, residual urine production.
\